At one point, a top Indian regulator contended that India could not afford to establish the same level of expectations for its inspections of its domestic business as the U.S. did. But with FDA actions against Indian drugmakers taking a financial toll, the country is now rethinking that position. The Health Ministry and Central Drug Standards Control Organization (CDSCO), will work together on looking at the standards and guidelines of health regulators in other countries, with an emphasis on the U.S. model. FiercePharmaAsia story | More